Rekvina Labs Ltd
₹ 44.0
1.99%
22 Apr
- close price
- Market Cap ₹ 26.5 Cr.
- Current Price ₹ 44.0
- High / Low ₹ 44.0 / 6.75
- Stock P/E
- Book Value ₹ -0.63
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 5.00
Pros
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.08 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | 0.00 | 0.00 | 0.00 | 0.55 | |
| 0.06 | 0.05 | 0.03 | 0.12 | 0.05 | 0.10 | 0.15 | 0.06 | 0.04 | 0.00 | 0.02 | 0.14 | 0.78 | |
| Operating Profit | 0.02 | 0.03 | 0.00 | -0.06 | -0.05 | -0.10 | -0.15 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.23 |
| OPM % | 25.00% | 37.50% | 0.00% | -100.00% | -41.82% | ||||||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | 0.03 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.23 |
| Tax % | 0.00% | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| 0.02 | 0.02 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.23 | |
| EPS in Rs | 0.02 | 0.02 | 0.00 | -0.05 | -0.02 | -0.07 | 0.00 | -0.05 | -0.07 | 0.00 | -0.02 | -0.12 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -37% |
| TTM: | -156% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 62% |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | -2.36 | -2.33 | -2.45 | -2.51 | -2.53 | -2.61 | -2.86 | -2.92 | -3.00 | -3.00 | -3.21 | -3.35 | -3.77 |
| 0.00 | 0.00 | 0.01 | 0.01 | 0.17 | 0.21 | 0.00 | 0.00 | 0.00 | 0.08 | 0.04 | 0.25 | 0.81 | |
| 0.08 | 0.09 | 0.09 | 0.13 | 0.14 | 0.19 | 0.13 | 0.15 | 0.18 | 0.11 | 0.17 | 0.12 | 0.02 | |
| Total Liabilities | 0.73 | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 0.07 |
| 0.27 | 0.27 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 |
| 0.41 | 0.45 | 0.46 | 0.44 | 0.59 | 0.60 | 0.08 | 0.04 | -0.01 | 0.00 | 0.01 | 0.03 | 0.07 | |
| Total Assets | 0.73 | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 0.07 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | ||
| 0.01 | 0.02 | 0.07 | -0.07 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | ||
| 0.00 | 0.01 | 0.00 | 0.16 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.21 | ||
| Net Cash Flow | 0.00 | 0.00 | 0.03 | 0.10 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.02 | |
| Free Cash Flow | -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | |
| CFO/OP | -33% | 67% | -20% | 20% | 7% | 17% | 50% | 50% | 136% |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 730.00 | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | |||||||
| Inventory Days | 0.00 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 730.00 | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | |||||||
| Working Capital Days | 1,368.75 | 1,460.00 | 4,015.00 | 1,460.00 | -1,642.50 | |||||||
| ROCE % | 3.10% | 4.51% | 0.00% | -11.11% | -3.45% | -12.70% | -50.00% | -160.00% | 0.00% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Number |
|
|||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 10 Apr
- Shareholder Meeting / Postal Ballot-Outcome of EGM 10 Apr
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
6 Apr - Rekvina Labs says Annual Secretarial Compliance Report is not applicable under Regulation 15(2) exemption.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr
-
Announcement under Regulation 30 (LODR)-Open Offer - Updates
2 Apr - Mandatory open offer to buy 28,90,100 shares at ₹10; acquirers may gain 77.33% post-offer.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Delisting & Relisting
Trading in the Company’s equity shares, earlier suspended by the BSE due to non-compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015[1][2], has been revoked with effect from January 07, 2026. Pursuant to SEBI Master Circular dated November 11, 2024, and upon compliance with applicable requirements, including payment of annual listing fees, trading in the Company’s securities has resumed in the “XT” group[3] and shall be included under the “X” group with effect from January 20, 2026.[4]